IP Library › Granted Patent US 10,954,222
Granted Patent B2
US 10,954,222 · App. 14/376,671 · Granted Mar 23, 2021

Benzothiophene compound, alternative autophagy-inducing agent and anticancer agent including the compound as active ingredient, and method for screening for compound having anticancer activity

Inventors: Shigeomi Shimizu (Bunkyo-ku, JP); Takamitsu Hosoya (Bunkyo-ku, JP); Michiko Murohashi (Bunkyo-ku, JP); Suguru Yoshida (Bunkyo-ku, JP)
Assignee: National University Corporation Tokyo Medical and Dental University
C07D409/04A61K31/381A61K49/0008C07D333/68G01N33/5011G01N2500/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,954,222
App. No.
14/376,671
Granted
Mar 23, 2021
Kind
B2
Abstract

It has been found that efficient screening for a compound having anticancer activity can be achieved by selecting a compound having activity to induce alternative autophagy using, as an index, formation of fluorescent bright spots due to aggregation of a lysosomal protein to which a fluorescent protein is attached in cells expressing the lysosomal protein. In addition, it has been found that a benzothiophene compound represented by the following general formula (1) has alternative autophagy-inducing activity and anticancer activity:

Claims (18)

1. A method for inducing alternative autophagy, comprising

introducing a benzothiophene compound represented by the following general formula (1) into any one of a cultured cell and an animal:

in the formula (1), R 1 is an optionally substituted 5- to 10-membered aromatic carbon ring, an optionally substituted 5- to 10-membered aromatic heterocycle, or a group represented by —R 6 —R 7 , R 2 is a halogen atom, a hydroxyl group, or a group represented by —O—R 6 —R 7 or —O—R 6 —R 8 , R 3 is a hydrogen atom or a group represented by —C(═O)R 9 , R 4 is a linear, branched, or cyclic alkyl group having 1 to 6 carbon atoms, and R 5 is an oxygen atom or an imino group, and also in the formula (1), R 6 s, which may be the same or different, each independently is a linear, branched, or cyclic alkylene group having 1 to 6 carbon atoms, R 7 s, which may be the same or different, each independently is an amino group optionally substituted by a linear, branched, or cyclic alkyl group having 1 to 6 carbon atoms, a linear, branched, or cyclic alkenyl group having 2 to 6 carbon atoms, or a linear, branched, or cyclic hydroxyalkyl group having 1 to 6 carbon atoms, R 8 is an optionally substituted 5- to 10-membered aromatic carbon ring or an optionally substituted 5- to 10-membered aromatic heterocycle, and R 9 is a linear, branched, or cyclic alkyl group having 1 to 6 carbon atoms, an optionally substituted 5- to 10-membered aromatic carbon ring, or an optionally substituted 5- to 10-membered aromatic heterocycle, and inducing alternative autophagy in any one of the cultured cell or the animal.

2. At least one benzothiophene compound selected from the group consisting of the following (a) and (b):

(a) a benzothiophene compound represented by the following general formula (1):

in the formula (1), R 1 is an optionally substituted 5- to 10-membered aromatic carbon ring or an optionally substituted 5- to 10-membered aromatic heterocycle, R 2 is a halogen atom, a hydroxyl group, or a group represented by —O—R 6 —R 7 or —O—R 6 —R 8 , R 3 is a hydrogen atom or a group represented by —C(═O)R 9 , R 4 is a linear, branched, or cyclic alkyl group having 1 to 6 carbon atoms, and R 5 is an oxygen atom or an imino group, and also in the formula (1), R 6 is a linear, branched, or cyclic alkylene group having 1 to 6 carbon atoms, R 7 is an amino group optionally substituted by a linear, branched, or cyclic alkyl group having 1 to 6 carbon atoms, a linear, branched, or cyclic alkenyl group having 2 to 6 carbon atoms, or a linear, branched, or cyclic hydroxyalkyl group having 1 to 6 carbon atoms, R 8 is an optionally substituted 5- to 10-membered aromatic carbon ring or an optionally substituted 5- to 10-membered aromatic heterocycle, and R 9 is a linear, branched, or cyclic alkyl group having 1 to 6 carbon atoms, an optionally substituted 5- to 10-membered aromatic carbon ring, or an optionally substituted 5- to 10-membered aromatic heterocycle; and

(b) a benzothiophene compound represented by the general formula (1):

in the formula (1), R 1 is a halogen atom, R 2 is a halogen atom or a group represented by —O—R 6 —R 7 , R 3 is a group represented by a hydrogen atom, R 4 is a linear, branched, or cyclic alkyl group having 1 to 6 carbon atoms, and R 5 is an oxygen atom or an imino group, and also in the formula (1), R 6 is a linear, branched, or cyclic alkylene group having 1 to 6 carbon atoms, and R 7 is an amino group optionally substituted by a linear, branched, or cyclic alkyl group having 1 to 6 carbon atoms, a linear, branched, or cyclic alkenyl group having 2 to 6 carbon atoms, or a linear, branched, or cyclic hydroxyalkyl group having 1 to 6 carbon atoms,

and the benzothiophene compound having alternative autophagy-inducing activity.

3. An anticancer agent comprising the benzothiophene compound according to claim 2 as an active ingredient, and any one of pharmacologically acceptable carriers and media.

4. A method for treating cancer, comprising a step of administering the benzothiophene compound according to claim 2 to a patient.

5. A benzothiophene compound represented by the following general formula (1):

in the formula (1), R 1 is a group selected from the following groups

R 2 is a group represented by —O—C 2 H 4 —N(C 2 H 5 ) 2 , R 3 is a group represented by —C(═O) CH 3 , R 4 is a group represented by —C 2 H 5 , R 5 is an oxygen atom.

6. An anticancer agent comprising the benzothiophene compound according to claim 5 as an active ingredient and any one of pharmacologically acceptable carriers and media.

7. A method for inducing alternative autophagy, comprising

introducing the benzothiophene compound according to claim 2 into any one of a cultured cell and an animal, and

inducing alternative autophagy in any one of the cultured cell and the animal.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2014
From: SHIMIZU, SHIGEOMI; HOSOYA, TAKAMITSU; MUROHASHI, MICHIKO; YOSHIDA, SUGURU
To: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
Reel/Frame 034021/0553 →
Priority Claims (2)
JP JP2012-026373 · Feb 9, 2012 · national
JP JP2012-026377 · Feb 9, 2012 · national
Continuity (1)
Related Publication 20150056141A1 · Feb 26, 2015